/ 2 items

#CATX↓

CATX/ 10/21/2025 · 3:36 AM

Perspective Therapeutics Stock Plunges 29% Despite 'Remarkable' Safety Data from Cancer Drug Trial

Perspective Therapeutics shares fell 29% to $3.19 after presenting Phase 1/2a trial data for VMT-alpha-NET. Analysts split on outlook despite favorable safety profile and $174M cash position through late 2026.

Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body.

CATX/ 10/10/2025 · 8:24 AM

Perspective Therapeutics: A Buy Rating for the Next-Gen Radiopharmaceutical Leader

BTIG analyst sees Perspective Therapeutics as "next-gen radiopharmaceutical leader" with strong competitive advantages and upcoming catalysts through 2026.